Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges - Takeaways - MDSpire

Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges

  • By

  • Jing Li

  • Shixiang Dong

  • Dongdong Hu

  • Wen Feng

  • July 9, 2026

  • 0 min

Share

  • 1

    Endometrial cancer is a prevalent malignancy in women, with approximately 417,000 new cases and 97,000 deaths reported in 2020.

  • 2

    Fertility-sparing treatment (FST) allows young women with endometrial cancer to preserve fertility before standard treatment.

  • 3

    Molecular classification reveals that patients with POLE mutations have better prognosis, while those with dMMR face higher recurrence rates.

  • 4

    Immune checkpoint inhibitors (ICIs) show potential in enhancing outcomes for patients undergoing fertility-sparing treatment for endometrial cancer.

  • 5

    Hysteroscopic resection combined with progestin therapy is currently the most effective method for fertility-sparing treatment.

Original Source(s)

Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges

  • by Jing Li, Shixiang Dong, Dongdong Hu, Wen Feng

  • July 9, 2026

Related Content

Case Report: Thoracic SMARCA4-deficient undifferentiated tumor with extraocular muscle metastasis: a rare case hidden in diplopia

Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study

The use of motion tracking technology to support an exercise intervention for children and young people with cancer: perspectives of users and healthcare professionals in the FORTEe trial